PZPia Susann Zeiner

Pia Susann Zeiner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pia Susann Zeiner has a total of 201 co-authors. Here are the top co-authors by number of shared publications:

  • Joachim P. Steinbach

    Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany; Goethe University Frankfurt, University Hospital, University Cancer Center (UCT), Frankfurt, Germany; Goethe University Frankfurt, Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Research Center (DKFZ) Heidelberg, Germany and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany

    9 shared publications
  • Patrick Nikolaus Harter

    Institute of Neuropathology, LMU Medizin Ludwig‐Maximilians‐Universität München Munich Germany

    7 shared publications
  • Michael Ronellenfitsch

    Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.

    6 shared publications
  • Patrick N. Harter

    Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität München, Munich, Germany

    6 shared publications
  • Karl H. Plate

    Goethe University Frankfurt, University Hospital, University Cancer Center (UCT), Frankfurt, Germany; Goethe University Frankfurt, University Hospital, Institute of Neurology (Edinger-Institute), Frankfurt, Germany; Goethe University Frankfurt, Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Research Center (DKFZ) Heidelberg, Germany and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany

    5 shared publications
  • Katharina J. Weber

    Goethe University Frankfurt, University Hospital, University Cancer Center (UCT), Frankfurt, Germany; Goethe University Frankfurt, University Hospital, Institute of Neurology (Edinger-Institute), Frankfurt, Germany; Goethe University Frankfurt, Frankfurt Cancer Institute (FCI), Frankfurt, Germany; German Cancer Research Center (DKFZ) Heidelberg, Germany and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt, Germany

    5 shared publications

Latest Publications

  • Open Access

    Methylation profiling and alternative classification approaches in a glioma-enriched FFPE stereotaxic biopsy cohort

    by Katharina Johanna Weber, Jürgen Hench, Markus Zumpt, Thomas Eska, Moritz Armbrust, Pia Susann Zeiner, Tabea Isabelle Hartung, Viktoria Ruf, Eike Steidl, Mareike Dettki, et al.

    DNA methylation profiling of CNS tumors supports and refines histological diagnoses. Tumor DNA methylation signatures allow for an alignment with reference methylation classes and copy number profiling required for molecular grading. Overall, and especially in cases with limited tissue like in stereotaxic (STX) biopsies, there is a need for informed triage to most promising analysis techniques. Here, we investigated the diagnostic potential and accuracy of DNA methylation profiling and molecular grading in STX samples. FFPE samples of 237 patients were subjected to DNA methylation analysis including the Heidelberg (v11b4), Bethesda (v2) and EpiDiP brain tumor classifiers, copy number profiling and tumor deconvolution using MethylCIBERSORT. 90.5% of samples ( n = 232) were allocated DNA methylation classes, with 61.6% reaching Heidelberg classifier scores of > 0.84. Indicatory copy number variations (CNVs) were detectable in 96.9% of cases. Recursive partitioning supported by a resampling-based validation with repeated random subsampling pointed towards brain tumor classifier dependent minimum analyte inputs to reach robust calibrated scores for DNA methylation class allocation. Successful integrative diagnostics furthermore depended on pre-classifier H&E diagnoses with 96.2% of H&E malignant diffuse gliomas, 91.5% of H&E diffuse gliomas but only 60% of H&E circumscribed gliomas classifiable using the Heidelberg brain tumor classifier. When the alternative classifiers EpiDiP and Bethesda were used, higher DNA input amounts ameliorated the classification robustness. Nevertheless, diagnostics of high-grade gliomas in midline location and lower-grade glial/glioneuronal tumors posed a challenge. Our findings demonstrate the broad applicability of DNA methylation profiling and molecular grading to small brain tumor specimens under the caveat of certain tumors and locations potentially benefiting from additional molecular as well as computational approaches to increase methylation signals relevant for classification in the future.


  • Open Access

    Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease

    by Paula Nieto, Svenja Klinsing, Ginevra Caratù, Mareike Dettki, Domenica Marchese, Katharina J. Weber, Samuel Morabito, Patricia Lorden, Irene Ruano, Katharina Imkeller, et al.


  • Open Access

    Glioma‑associated microglia and macrophages as a potential target for mTOR inhibition in glioblastoma

    by Pia S. Zeiner, Michael Schulz, Jana Schomber, Jan-Béla Weinem, Nadja I. Lorenz, Benedikt Sauer, Bastian Roller, Katharina J. Weber, Anna-Luisa Luger, Annemarie Berger, et al.

    Glioma‑associated microglia/macrophages (GAM) constitute the predominant immune cell population in glioblastoma (GB). Both GB cells and GAM exhibit upregulated mTOR signaling. The present study aimed to investigate the effects of pharmacological mTOR inhibition (mTORi) specifically on GAM. The effects of mTORi on signal transduction, cell growth and viability were analyzed in immortalized microglia cell lines. Additionally, a comprehensive analysis of the GAM phenotype was conducted, including whole transcriptome analyses and cytokine profiling. Effects were investigated in a tumor cell/GAM co‑culture model under mTORi with rapamycin or torin2 or treatment with temozolomide, the standard chemotherapy agent for patients with GB. In the in vitro model, mTORi had significant effects on central biological functions of GAM, resulting in reduced proliferation and oxygen consumption. Additionally, treatment with mTORi induced a pro‑inflammatory phenotype in microglia cell lines. These findings demonstrate the relevance of mTOR signaling on GAM biology. Moreover, they provide rationales for therapeutic interventions targeting mTOR signaling specifically in GAM as a potential novel treatment strategy.


  • Open Access

    Decoding the immune response in leptomeningeal disease through single-cell sequencing of cerebrospinal fluid

    by Paula Nieto, Svenja Klinsing, Ginevra Caratu, Mareike Dettki, Domenica Marchese, Katharina J. Weber, Samuel Morabito, Patricia Lorden, Irene Ruano, Katharina Imkeller, et al.

    Assessing anti-tumor immune responses and immune microenvironments in central nervous system (CNS) neoplasms, such as brain tumors and leptomeningeal disease (LMD), provides prognostic insights and predictive biomarkers. Liquid biopsy of the cerebrospinal fluid (CSF) represents a promising minimally-invasive approach, but its ability to reflect immune responses against tumors remains unclear. Here, we used single-cell sequencing of CSF cells and spatial transcriptomics of CNS lesions to compare and contrast LMD patients with CNS lymphoma (CNSL), glioblastoma (GB) and brain metastases (BrM), to neuroinflammatory CNS disorders. We identified disease-specific CSF environments, reflecting parenchymal tumor microenvironment features. CNSL showed robust T cell responses, while BrM and GB were dominated by both blood-derived and tissue-resident myeloid cells. Longitudinal CSF sampling unveiled mechanisms of disease progression and therapy resistance, highlighting the potential of CSF liquid biopsies for uncovering disease biology, discovering cellular biomarkers and developing personalized therapies for CNS neoplasms.

  • Open Access

    Detection of diagnostic somatic copy number alterations from cerebrospinal fluid cell-free DNA in brain tumor patients

    by Svenja Klinsing, Julia Beck, Katharina J. Weber, Kirsten Bornemann-Kolatzki, Mareike Dettki, Hans Urban, Bastian Roller, Kai U. Chow, Henning Reis, Peter J. Wild, et al.

    The gold standard for precise diagnostic classification of brain tumors requires tissue sampling, which carries relevant procedural risks. Brain biopsies often have limited sensitivity and fail to address tumor heterogeneity, because small tissue parts are being examined. This study aims to explore the detection and quantification of diagnostically relevant somatic copy number aberrations (SCNAs) in cell-free DNA (cfDNA) extracted from cerebrospinal fluid (CSF) in a real-world cohort of patients with defined brain tumor subtypes. A total of 33 CSF samples were collected from 30 patients for cfDNA extraction. Shallow whole-genome sequencing was conducted on CSF samples containing > 3ng of cfDNA and corresponding tissue DNA from nine patients. The sequencing cohort encompassed 26 samples of 23 patients, comprising 12 with confirmed CNS cancer as compared to 11 patients with either ambiguous CNS lesions (n = 5) or non-cancer CNS lesions (n = 6). After mapping and quality filtering SCNAs were called by depth-of-coverage analyses with a binning of 5.5 Mbp. SCNAs were exclusively identified in CSF cfDNA from brain tumor patients (10/12, 83%). In tumor patients, SCNAs were detectable in cfDNA from all patients with, but also in five of seven patients without tumor cells detected by CSF cytopathology. A substantial number of shared SCNAs were traceable between tissue and CSF in matched pair analyses. Additionally, some SCNAs unique to either CSF or tissue indicating spatial heterogeneity or tumor evolution. Also, diagnostically relevant genomic alterations as well as essential and desirable SCNAs as implemented in the current WHO classification of CNS tumors for certain primary brain tumor subtypes were traceable. In summary, this minimally invasive cfDNA-based LB approach employing shallow whole genome sequencing demonstrates potential for providing a molecularly informed diagnosis of CNS cancers, mapping tumor heterogeneity, tracking tumor evolution, and surveilling tumor patients. Further prospective trials are warranted.


  • Open Access

    Intrathecal IgM synthesis as a diagnostic marker in patients with suspected CNS lymphoma

    by Raphael Reinecke, Kolja Jahnke, Martha Foltyn‐Dumitru, Karsten Lachner, Moritz Armbrust, Katharina J. Weber, Pia S. Zeiner, Marcus Czabanka, Uta Brunnberg, Sylvia Hartmann, et al.

    For CNS lymphomas (CNSL), there is a high need for minimally invasive and easily obtainable diagnostic markers. Intrathecal IgM synthesis can easily be determined in routine CSF diagnostics. The aim of this study was to systematically investigate the diagnostic potential of intrathecal IgM synthesis in primary and secondary CNSL (PCNSL and SCNSL). In this retrospective study, patients with a biopsy‐proven diagnosis of PCNSL or SCNSL were compared with patients with other neurological diseases in whom CNSL was initially the primary radiological differential diagnosis based on MRI. Sensitivity and specificity of intrathecal IgM synthesis were calculated using receiver operating characteristic curves. Seventy patients with CNSL were included (49 PCNSL and 21 SCNSL) and compared to 70 control patients. The sensitivity and specificity for the diagnosis of CNSL were 49% and 87%, respectively, for the entire patient population and 66% and 91% after selection for cases with tumor access to the CSF system and isolated intrathecal IgM synthesis. In cases with MRI‐based radiological suspicion of CNSL, intrathecal IgM synthesis has good specificity but limited sensitivity. Because of its low‐threshold availability, analysis of intrathecal IgM synthesis has the potential to lead to higher diagnostic accuracy, especially in resource‐limited settings, and deserves further study. image

  • Open Access

    Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses

    by Thomas Zeyen, Daniel Paech, Johannes Weller, Niklas Schäfer, Theophilos Tzaridis, Cathrina Duffy, Louisa Nitsch, Matthias Schneider, Anna-Laura Potthoff, Joachim Peter Steinbach, et al.

  • Open Access

    Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience

    by Sebastian E. Koschade, Jan A. Stratmann, Pia S. Zeiner, Fabian Finkelmeier, Jörg Chromik, Björn Steffen, Hubert Serve, Christian H. Brandts, Olivier Ballo

    Cranial imaging (CI) is a widely used diagnostic procedure, especially in acute myeloid leukemia (AML) patients with suspected bleeding or infection. However, common clinical decision rules to guide CI do not apply to AML patients and the diagnostic yield and outcomes of CI for AML patients are largely unknown. We retrospectively evaluated all CI from newly diagnosed non-promyelocytic AML patients receiving intensive induction or consolidation chemotherapy between 2007 and 2019 for imaging indications, diagnostic yield, and consequences. A total of 110 of 462 patients (24%) received CI for 152 imagings in distinct clinical situations. Forty-four patients (40%) had at least one new and acute pathological finding. Main indication was focal neurologic deficit, craniocerebral trauma, and suspected cerebral hypertension. The most common new finding was intracranial hemorrhage (13% of all imagings), followed by sinusitis (9%). CI led to therapy change in 21 patients. There were no clear associations between indications, laboratory values, and a positive imaging. Positive imaging was associated with adverse overall survival. Our study suggests that the overall rate of ordered CI was appropriate and that CI should generally be performed at a low threshold. A systematized approach to CI may further increase diagnostic yield but is complicated by variable clinical presentation.

  • Open Access

    Concurrent gliomas in patients with multiple sclerosis

    by Katharina Sahm, Tobias Kessler, Philipp Eisele, Miriam Ratliff, Elena Sperk, Laila König, Michael O. Breckwoldt, Corinna Seliger, Iris Mildenberger, Daniel Schrimpf, et al.

    Background Concurrent malignant brain tumors in patients with multiple sclerosis (MS) constitute a rare but paradigmatic phenomenon for studying neuroimmunological mechanisms from both molecular and clinical perspectives. Methods A multicenter cohort of 26 patients diagnosed with both primary brain tumors and multiple sclerosis was studied for disease localization, tumor treatment-related MS activity, and molecular characteristics specific for diffuse glioma in MS patients. Results MS neither predisposes nor protects from the development of gliomas. Patients with glioblastoma WHO grade IV without IDH mutations had a longstanding history of MS, whereas patients diagnosed with IDH-mutant astrocytoma WHO grade II received multiple sclerosis diagnosis mostly at the same time or later. Concurrent MS was associated with a lesser extent of tumor resection and a worse prognosis in IDH-mutant glioma patients (PFS 32 vs. 64 months, p=0.0206). When assessing tumor-intrinsic differences no distinct subgroup-defining methylation pattern was identified in gliomas of MS patients compared to other glioma samples. However, differential methylation of immune-related genetic loci including human leukocyte antigen locus on 6p21 and interleukin locus on 5q31 was found in MS patients vs. matched non-MS patients. In line, inflammatory disease activity increased in 42% of multiple sclerosis patients after brain tumor radiotherapy suggesting a susceptibility of multiple sclerosis brain tissue to pro-inflammatory stimuli such as ionizing radiation. Conclusions Concurrent low-grade gliomas should be considered in multiple sclerosis patients with slowly progressive, expansive T2/FLAIR lesions. Our findings of typically reduced extent of resection in MS patients and increased MS activity after radiation inform future treatment decisions. Key points – Disease history and sequence of diagnosis differ in MS patients with high-vs low-grade glioma – Gliomas of MS patients harbor subtle methylation changes in immune-related genetic regions – Brain tumor radiotherapy is followed by MS disease activity Importance of the study Immune escape is a hallmark of diffuse glioma, while inflammation is the underlying mechanism of multiple sclerosis. These opposing mechanisms concur in patients that suffer in parallel from multiple sclerosis and glioma. This study is the first to investigate the tumor characteristics, tumor treatment responses and effect on multiple sclerosis activity of a cohort of patients with both diseases. The data warrant caution in the interpretation of suspicious lesions in imaging and suggests risk loci for the observed detrimental effects of radiation specific to MS patients.

  • Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma

    by Pia S. Zeiner, Katharina Filipski, Natalie Filmann, Marie-Thérèse Forster, Martin Voss, Emmanouil Fokas, Ulrich Herrlinger, Patrick N. Harter, Joachim P. Steinbach, Michael W. Ronellenfitsch

    Objective: To investigate the association of radiochemotherapy-induced cytopenia with sex of glioma patients and its potential impact on survival. Methods: We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy (RCT) in 492 glioma patients. Histological grading, molecular pathology, surgical procedures, adjuvant chemotherapy subsequent to the RCT phase and overall survival (OS) were recorded. The extent of cytopenia was correlated with sex and outcome. Results: Treatment-induced severe cytopenia (leuko-, lympho-, neutro- and thrombocytopenia) was more frequent in women than men (44 vs. 18%, p-value 0.0002). In women with IDH-wildtype high-grade astrocytomas there was a negative correlation of severe cytopenia in general and thrombocytopenia in specific during temozolomide RCT with OS independent from other predictors (92 (77-111) vs. 73 (21-127) weeks, p-values <0.05). In men there was also a trend for this unfavorable effect. Additionally, severe cytopenia in all blood cell lineages correlated with reduced temozolomide dose exposure during RCT (all p-values <0.05 in the total cohort) and reduced dose exposure was independently associated with worse OS (hazard ratios for OS complete vs. reduced temozolomide dose in the total/female cohort: 0.66 (0.47-0.92) and 0.4 (0.24-0.69), p-values <0.05). Conclusions: Our analysis of treatment-induced cytopenia in a large cohort of glioma patients (i) confirms that women are at higher risk and (ii) demonstrates an association of cytopenia in women with shortened survival. Classification of Evidence: This study provides class II evidence that women with glioma treated with temozolomide-based concomitant radiochemotherapy have more frequent treatment-induced severe cytopenia than men and that severe myelosuppression correlates with worse OS in women.